Permanent J Code Boosts Access to ZUSDURI Bladder Therapy
PRINCETON, N.J. | January 5, 2026 — UroGen Pharma Ltd. has announced that a permanent HCPCS Level II J...
Bladder cancer therapy
Advertisement
FDA Approves J&J’s INLEXZO™, Redefining Bladder Cancer Care
September 9, 2025 – Raritan, N.J. – In a landmark regulatory milestone, Johnson & Johnson (NYSE: JNJ) announced U.S....
Advertisement
